1. A mixed-method study on antimicrobial resistance infection drivers in neonatal intensive care units: pathways, risks, and solutions
- Author
-
Almaw Genet Yeshiwas, Gashaw Melkie Bayeh, Tilahun Degu Tsega, Sintayehu Simie Tsega, Asay Alamneh Gebeyehu, Zufan Alamrie Asmare, Rahel Mulatie Anteneh, Amare Genetu Ejigu, Ahmed Fentaw Ahmed, Zeamanuel Anteneh Yigzaw, Abathun Temesgen, Anley Shiferaw Enawgaw, Getasew Yirdaw, Wosenyelesh Desalegn, and Chalachew Yenew
- Subjects
Antimicrobial resistance (AMR) ,NICU ,Coagulase-negative staphylococci (CONS) ,Infection prevention and control (IPC) ,Amikacin ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Antimicrobial resistance (AMR) in neonatal intensive care units (NICUs) complicates treatment of healthcare-associated infections, causing high morbidity and mortality, especially among low-birth-weight and critically ill infants. This study evaluates AMR prevalence, risk factors, outcomes and infection control measures at Felege Hiwot Hospital, aiming to guide clinical practices, antimicrobial stewardship, and improved neonatal health outcomes. Methods This mixed-methods study (Oct 2022–Jun 2023) assessed AMR in NICU neonates by analyzing 420 blood samples, environmental swabs, and staff insights. Bivariable and multivariable regressions identified significant variables, and content analysis was used for qualitative data. Results Out of 420 samples, 35% tested positive for AMR pathogens, with Coagulase-Negative Staphylococci (16.7%), Klebsiella pneumoniae (12.9%), and Acinetobacter spp. (5.6%) being the most prevalent. Resistance rates for Gentamicin, Cotrimoxazole, and Ciprofloxacin were alarmingly high (98–100%), while Amikacin demonstrated low resistance (3.0-5.56%), indicating potential efficacy. Among the neonates admitted, 91.8% survived, and 8.2% succumbed. Risk factor analysis revealed that improper PPE usage (AOR 3.90, p
- Published
- 2025
- Full Text
- View/download PDF